Education
About Us
Working with TipRanks
Follow Us
Urologix (ULGX)
OTHER OTC:ULGX
ULGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume700.00
Average Volume (3M)250.00
Market Cap
$2.18K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-109.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,818,000
10 Day Avg. Volume250
30 Day Avg. Volume250
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.18% Other Institutional Investors
99.82% Public Companies and
Individual Investors
ULGX FAQ
What was Urologix’s price range in the past 12 months?
Urologix lowest stock price was $0.02 and its highest was $0.02 in the past 12 months.
What is Urologix’s market cap?
Urologix’s market cap is $2.18K.
When is Urologix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Urologix’s earnings last quarter?
Currently, no data Available
Is Urologix overvalued?
According to Wall Street analysts Urologix’s price is currently Overvalued.
Does Urologix pay dividends?
Urologix does not currently pay dividends.
What is Urologix’s EPS estimate?
Urologix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Urologix have?
Urologix has 21,818,000 shares outstanding.
What happened to Urologix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Urologix?
Currently, no hedge funds are holding shares in ULGX
---
Company Description
Urologix
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.
---
---